Finnish Institute to Use Labcyte Tech to Enhance Cancer Testing Studies | GenomeWeb

NEW YORK (GenomeWeb News) – Labcyte said today that the Institute for Molecular Medicine Finland, known as FIMM, will use Labcyte's acoustic liquid handling technology in its small molecule-based personalized cancer medicine programs, under a new collaboration.

Helsinki-based FIMM has already used Labcyte's acoustic liquid handling technology to generate better data and to reduce the costs of its small-molecule screening for the past three years, Labcyte CEO Mark Fischer-Colbrie said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.